Home › Markets › Health Care › RYTM

Rhythm Pharmaceuticals Inc. (RYTM)

RYTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$86.61
-3.57% on the day
Market cap
$6.0B
Mid cap
Revenue · 2025
$189.8M
+45.8% on 2024
Net income · 2025
-$197K
-0.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerRYTM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001649904
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$189.8M
Net income-$197K
Operating income-$192.0M
Net margin-0.1%
Operating margin-101.2%
Revenue growth+45.8%
Cash$54.3M
Total assets$480.2M
P/E (computed)Net income was not positive
P/S (computed)31.4×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-26
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-08-04
Latest current report8-K2026-08-04
Latest proxyDEFA14A2026-05-29

Source: SEC EDGAR submissions feed, 835 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.6%
1 month-10.1%
3 months-18.0%
Year to date-18.7%
1 year-13.6%
From 52-week high-26.0%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LGNDLigand Pharmaceuticals Incorporated$303.53-2.44%$6.1B
BLTEBelite Bio Inc$151.87-4.24%$6.1B
KNSAKiniksa Pharmaceuticals International plc$78.53-0.90%$6.1B
ALKSAlkermes plc$39.73-1.32%$6.7B
PRAXPraxis Precision Medicines Inc.$243.34-3.20%$6.8B
AMRXAmneal Pharmaceuticals Inc.$19.57-2.30%$6.8B
MIRMMirum Pharmaceuticals Inc.$79.62-7.48%$5.2B
ERASErasca Inc.$14.78-4.40%$5.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier